Bone mineral density is associated with pre-treatment pain levels of complex regional pain syndrome type 1 and predicts the response to N-containing bisphosphonates
Lower BMD was associated with greater CRPS severity and better response to treatment. These findings support the roleof bone in CRPS pathogenesis and suggest that DXA-derived Z-scores may help identify patients most likely to benefit from bisphosphonates.
Authors
- Anna Lisa Piccinelli (ORCID: https://orcid.org/0000-0001-6102-2762)
- Camilla Benini (ORCID: https://orcid.org/0000-0002-8082-5023)
- Ombretta Viapiana (ORCID: https://orcid.org/0000-0003-1917-5655)
- Francesco Pollastri (ORCID: https://orcid.org/0009-0006-1691-2196)
- Maurizio Rossini (ORCID: https://orcid.org/0000-0001-9692-2293)
- Davide Gatti (ORCID: https://orcid.org/0000-0002-7471-3076)
- Angelo Fassio (ORCID: https://orcid.org/0000-0001-9187-232X)
- Carmela Dartizio
- Giovanni Adami (ORCID: https://orcid.org/0000-0002-8915-0755)
- V. Braga
- Pietro Maistri
Institutions
- University of Verona (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2025-03-13
- DOI
- https://doi.org/10.55563/clinexprheumatol/d4fdnb
- Primary Topic
- Pain Management and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Eli Lilly and Company